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Juvenile idiopathic arthritisRituximab is a monoclonal antibody directed against the CD20 antigen expressed on B cells and widely used in
the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis.
There is a growing amount of literature which suggests that rituximab may be useful for inﬂammatory ocular
diseases and intraocular lymphoma. Few cases have been reported on treatment of refractory scleritis,
peripherative ulcerative keratitis, uveitis and ocular surface inﬂammatory disorders. Rituximab may be
effective in the treatment of ocular inﬂammatory diseases in particular the most aggressive, recalcitrant and
sight-threatening forms of inﬂammation such as uveitis associated to juvenile idiopathic arthritis.
We review the literature covering the use of Rituximab in these conditions and report our results on the
efﬁcacy of Rituximab in the treatment of 8 children with very severe and long-standing uveitis who failed to
respond to one or more TNF blockers. Our patients showed improvement in activity of uveitis, reduction of
concomitant corticosteroids and immunosuppressants after a mean follow-up time of 14.87 months on
rituximab. No serious adverse events were encountered in our treated patients.
Although further studies are needed for assessing the efﬁcacy of rituximab and the exact dosing regimen,
rituximab may be considered as a treatment alternative in patients with the most aggressive forms of
inﬂammatory ocular diseases who fail to respond to conventional and anti-TNF immunosuppressive agents.ology, Scientiﬁc Institute San
32 Milan, Italy. Tel.: +39 02
rocchi).
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Anti CD20 Rituximab is a chimeric (murine and human)monoclonal
antibody directed against the CD20 molecule, a tetraspan membrane
protein found only on the surface of mature B cells [1–6]. The CD20
molecule displays a dynamic appearance ﬁrst evolving in the immature
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cells. By targeting CD20 the killing of B-cell precursor stem cells is
avoided. Long-lived plasma cells residing in the bone marrow are also
spared as most of them do not any longer carry the CD20 antigen. This
means that immunoglobulin formation against isoantigens and anti-
bodies against previously fought infectious agents are continuously
formed. The mechanism at which Rituximab causes B-cell death is not
fully understood. It is, however, likely to be a combination of antibody-
dependant cell-mediated cytotoxicity, complement-mediated lysis,
growth inhibition and apoptosis. In vivo experiments using a mouse
model of immunotherapy suggest that the most important mechanism
of action is via antibody-dependant cell-mediated cytotoxicity [1–6].
Themechanisms do, however, work in a complexmanner. For example,
lymphoma cells at different maturation stages respond differently to
Rituximab induced apoptosis and inhibition of proliferation.
Rituximab was ﬁrst approved by the FDA in 1997 for treatment of
patients with relapsed or refractory lymphoma. Since that time, its
therapeutic range has gradually expanded to also include non-
malignant B-cell dependent diseases. Of these, rheumatoid arthritis
(RA) is the autoimmune disease in which Rituximab has been most
extensively studied [4–8].
2. Drug safety and adverse events
The tolerability and safety of Rituximab has been well described in
the clinical trials of patients with RA and review articles on non-
Hodgkin's lymphoma [4,7–10]. The most frequent adverse events are
infusion reactions (30–35% with the ﬁrst infusion). Patients may
experience immediate infusion reactions of mild and transient
character [4,7–11]. Nevertheless, severe infusion reactions are
uncommon and their frequency is reduced by the use of concomitant
intravenous steroids. Serum sickness reactions occur more frequently
in patients with autoimmune diseases. As Rituximab is a chimeric
human/mouse antibody, human antichimeric antibodies (HACAs)
may occur and have been reported in about 9.2% of patients with RA.
These HACAs may be responsible for infusion reactions [9,10].
The main concern with the use of Rituximab in the treatment of
autoimmune diseases, especially when used with concomitant
immunosuppressive therapy, is the high incidence of systemic
infections, which can sometimes lead to fatal septicemia [9–11].
Variable degrees of rituximab-associated infectious risk have been
reported. Some patients with refractory autoimmune diseases, who
were treated with combined rituximab and immunosuppressants,
developed infectious complications. Conversely, no infectious
complications have been reported for patients in whom Rituximab
was initiated alone, without systemic corticosteroids or other
immunosuppressants [10]. To date, no studies comparing the
infectious risk of conventional immunosuppressants versus Ritux-
imab are available.
3. Rituximab in systemic autoimmune diseases
Several clinical studies have demonstrated the substantial impact of
rituximab for treatment of various systemic autoimmune diseases [1–
8,10–17]. Evidence of therapeutic effect is also mounting for numerous
autoimmune conditions such as rheumatoid arthritis, systemic lupus
erythematosus (SLE), Wegener's granulomatosis and anti-neutrophil
cytoplasmic antibody (ANCA)-associated vasculitis, idiopathic throm-
bocytopenic purpura, multiple sclerosis and Sjogren's syndrome
[4,7,12–15]. However, the treatment protocols applied in these studies
differ from each other in that infusions were given once weekly for 2 to
4 weeks, and the dosages were either ﬁxed at 500 mg or 2000 mg or
were 375 mg/m2 in other studies. A sustained B-cell depletion of naïve
and autoimmune cells was achieved, with peripheral blood CD20 cells
being lowor undetectable for up to 6 months, returning topretreatment
levels within 12 months. Earlier repopulation of B cells was observedafter rituximab monotherapy rather than after combination therapy
with immunosuppressive agents, such as methotrexate [2].
4. Rituximab in inﬂammatory eye diseases
Rituximab has been successfully used for the treatment of
refractory keratoconjunctivitis, scleritis [18–23], peripheral ulcerative
keratitis [24,25], uveitis [26–29] and ocular surface inﬂammatory
diseases such as cicatricial pemphigoid [30,31] also when associated
with systemic diseases. Experience in inﬂammatory ocular diseases is
still scarce with few case reports on its efﬁcacy.
5. Scleritis and orbital inﬂammation
Necrotizing scleritis and peripheral ulcerative keratitis are destruc-
tive forms of ocular inﬂammation of Wegener's granulomatosis usually
associated with active systemic vasculitis and can result in profound
visual loss. Successful effectiveness with Rituximab has been reported
on three patients with scleritis and peripherative ulcerative keratitis
associated with Wegener's granulomatosis [18,20–23]. Another case of
peripherative ulcerative keratitis associated to Wegener's granuloma-
tosis completely resolved with two Rituximab infusions, given accord-
ing to the protocol of 1000 mg/infusion at two weeks apart [24]. Some
authors showed limited evidence that scleritis and orbital inﬂammation
may respond to Rituximab, probably due to the presence of ﬁbrotic
nature of granulomas in Wegener's, especially when occurring retro-
orbital [22]. Taylor and colleagues reported clinical improvement in 10
patients with refractory granulomatous ocular Wegener's mainly
scleritis and orbital granulomas [21]. In the study by Taylor, patients
were treated with 2 doses of 1 mg each, 2 weeks apart, and B cell
depletion was associated with a trend toward decreased ANCA levels
and clinical improvement in both vasculitic and granulomatous
manifestations of the disease [21]. Ahmadi-Simab and colleagues
reported a case of refractory anterior scleritis associated with Sjögren's
syndrome that completely resolved after four infusions of Rituximab
given according to the oncologic protocol at the dose of 375 mg/m2 at
four-week intervals [19]. It is possible that thedifferent dosing regimens
used for refractory orbital inﬂammation associated with Wegener
granulomatosismaybe responsible for the reporteddifferent responses.
6. Sjogren's syndrome
Keratoconjunctivitis sicca (KCS) is the most common ocular
manifestation of Sjogren's syndrome; sicca syndrome, secondary to
lacrimal gland inﬂammation and reduction of lacrimal tear secretion
can induce severe corneal complications and may eventually lead to
bilateral blindness.
Preliminary experiences of Rituximab therapy inSjogren's syndrome
patients suggest that patients with more residual exocrine gland
function might better beneﬁt from treatment. Sicca syndrome
responded much better in the patient's perspective than in clinical
objective evaluation, with about half of the patients reporting an
improvement in oral andocular dryness,while objective tests (Schirmer
test) remained unchanged or worsened in all the patients [16,17].
Improvement in submandibular ﬂow rate, dry mouth score, IgM
rheumatoid factors (RF), fatigue, and health-related quality of life
tests, was also observed in Sjogren's patients after treatment with
Rituximab [17].
7. Ocular cicatricial pemphigoid
Ocular cicatricial pemphigoid (OCP) is one of the subsets within
the spectrum of mucous membrane pemphigoid, a family of
autoimmune blistering diseases with autoantibodies targeting various
glycoproteins in skin and/or mucous membranes [30]. The disease is
relentlessly progressive, usually slow, and often resulting in profound
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twelve patients with OCP treated with a combination of Rituximab
and intravenous immunoglobulin therapy [31].
8. Intraocular lymphoma
Primary intraocular lymphoma, is a hematopoietic tumor that
arises within the retina, vitreous, subretinal pigment epithelial space
or optic nerve head. Intraocular lymphoma may manifest with
different forms of uveitis called “masquerade syndrome”. The
malignancy is considered a subset of primary central nervous system
lymphoma, which is a variant of extra-nodal non Hodgkin lymphoma.
Malignant lymphocytes present in intraocular lymphoma express
certain B cell markers including CD 20 [32]. Therefore, intraocular use
of rituximab has been explored in animal models. No ocular toxicity
was found in rabbits and in humans treated with 1 mg of Rituximab
injected in the vitreous cavity. Further studies are necessary to
conﬁrm the lack of toxicity at this dose and whether this local therapy
is effective in human intraocular lymphoma [32,33].
9. Uveitis
Rituximab may be helpful in selected patients with chronic uveitis
refractory to corticosteroid and conventional immunosuppressants.
Tappeiner and colleagues reported improvement of endogenous
uveitis and associated cystoid macular edema in an adult patient
treated with Rituximab; the treatment also displayed a steroid-
sparing effect. However, the B-cell depletion in the peripheral blood
and the positive effect on uveitis were transient, since there was a
recurrence of inﬂammation after 6 and 9 months from Rituximab
treatment [26].
Davatchi and Sadreddini showed favorable results on the efﬁcacy
of Rituximab in intractable ocular lesions of patients with Behcet's
disease, in spite of the fact that it is mainly a T-cell driven disease
[27,28].
10. Children with juvenile idiopathic arthritis associated uveitis:
personal experience
Juvenile idiopathic arthritis (JIA) is the most common systemic
disorder associated with uveitis in childhood, accounting for approxi-
mately 75% of all pediatric anterior uveitis cases. Long-term ocular
complications of uveitis such as cataract, band keratopathy, posterior
synechia, glaucoma and maculopathy can lead to severe visual
impairment in about 38% of patients [34]. Visual outcome in long-
term follow-upof patients suffering from JIA-associateduveitis has been
described as poor, with one third of patients developing substantial
visual impairment and 10% becoming blind [34]. Aggressive immuno-
modulatory therapy is often introduced to improve the visual prognosis
and to reduce corticosteroid associated adverse events.With the advent
of biologic agents, tumor necrosis factor α (TNFα) antagonists have
been successfully used and have changed and markedly improved the
treatment options for JIA [35–37]. However, a subset of patients fails to
respond to TNFα blockers or is unable to tolerate these therapies and
may beneﬁt from switching to another drug.
B cells are clearly involved in the pathogenesis of oligoarticular JIA
and associated uveitis, as suggested not only by the very strong
association with ANA production in this JIA subset, but also by recent
studies on peripheral bloodmononuclear cells gene expression proﬁle
showing that B cell receptors signaling pathways is strongly
upregulated in patients with persistent oligoarthritis [38]. Therefore
B cells may be a rational target of biological treatment in JIA associated
uveitis. Based on this and on the favorable response in inducing long-
term remissions in different ocular and rheumatic inﬂammatory
diseases, we decided to treat with Rituximab eight patients with
recalcitrant and longstanding chronic JIA associated uveitis. Wepreviously reported our preliminary experience with Rituximab in
children with uveitis associated with JIA [39].
All patients attended the Pediatric Rheumatologic Unit at the
“Istituto Ortopedico G. Pini”, Milan and were always under the care of
the same uveitis specialist (EM). Patients included in the study were
those who had an inadequate response in controlling intra-ocular
inﬂammation to one or more TNF blockers (Etanercept, Inﬂiximab or
Adalimumab). Rituximab was given at the dose of 1000 mg per
infusion on days 1 and 15 and a recall 3rd infusion was scheduled at
12th month and 21 months according to the rheumatologic protocol
applied in the treatment of rheumatoid arthritis. Before Rituximab
infusion, to prevent the onset or reduce the frequency and severity of
infusion reactions, all patients received 100 mg of methylpredniso-
lone intravenously, oral paracetamol and antihistamines. Screening
before initiation of Rituximab treatment included serum biochemical
and hematologic proﬁles with complete hemogram, liver and renal
function tests, peripheral blood B lymphocytes count, chest X-ray and
electrocardiography. All patients have been already pre-screened for
the presence of active or latent tuberculosis since they have been
previously treated with TNF-blockers.
Ophthalmic and rheumatologic assessments were performed every
one or two months according to disease activity and response to
treatment. All patients were clinically monitored by the same pediatric
rheumatologist (IP) with complete physical examination and routine
laboratory test, repeated at eachofﬁcevisit. Data collected included: age,
gender, age at onset of uveitis and arthritis, characteristics of the uveitis,
ocular complications, JIA category according to ILAR classiﬁcation [40],
presence of ANA, RF and HLA-B27 antigens, previous systemic
immunosuppressant therapies, previous local (ocular) corticosteroid
therapy, number and dosage of Rituximab infusions, and follow-up on
Rituximab treatment.
The primary outcome measures evaluated were: clinical
response to treatment including decrease in disease activity
(intra-ocular inﬂammation), improvement in visual acuity, reduc-
tion of concomitant local and systemic corticosteroid and/or
immunosuppressants, occurrence of adverse events. Disease
activity was graded in accordance with the standardization uveitis
nomenclature (SUN) criteria [41]. Anterior chamber cells, as a
validated indicator for inﬂammatory activity and Snellen visual
acuity were graded before treatment and at every ophthalmologic
assessment.
Eight Caucasian patients (2 males and 6 females; 14 affected eyes)
with a mean age of 20.26±6.6 (SD) years (range: 13–34) affected by
JIA (oligo-extended in 5 patients, oligo-persistent in 2) and associated
uveitis were treated with Rituximab. Treatment indication was active
uveitis and failure to conventional immunosuppressants and anti-TNF
agents (Etanercept, Inﬂiximab, Adalimumab) due to inadequate
response. All patients were ANA positive and negative for RF and
HLA-B27 antigens. Themean age at onset of arthritis was 2.8±2.4 (SD)
years (range 1–8), while the mean age at onset of uveitis was 4.1±3.9
(SD) years (range 1–12); the mean ocular disease duration was
16.12 years (range 11–26) and the mean duration of arthritis was
17.35 years (range 11–26). In six out of eight patients the ocular
involvement was bilateral (total number of treated eyes: 14). Ocular
complications present at the beginning of Rituximab treatment were:
posterior synechia (13 out of 14 affected eyes), cataract (8/14 eyes),
band keratopathy (11/14 eyes), glaucoma (5/14 eyes). Table 1 shows
the details of previous and concomitant treatments for each patient.
Before starting the Rituximab treatment, all patients have been
unsuccessfully treated with different consecutive TNFα blockers;
patients #4 and #6were switched on two agents, while the remaining
patients underwent a switch of three different anti-TNF. The reason
for switching among anti-TNF was either inefﬁcacy on the uveitis or
occurrence of adverse events. Patients #5 and #8 were also treated
with a short-term course of chlorambucil before and after being
treated with TNF blockers. Although long-term remission with
Table 1








employed at last visit
Systemic steroid before rituximab and at
last visit (prednisolone mg/day)
Topical steroids before rituximab and
at last visit (daily frequency)
1 MTX, CSA Etan, Inﬂ, Adal None 7.5–None 3–1
2 MTX, CSA Etan, Inﬂ, Adal None 25–12.5 4–1
3 MTX, CSA Etan, Inﬂ, Adal None None–None 4–2
4 MTX, CSA, AZA Inﬂ, Adal CSA 25–12.5 3–1
5 MTX, CSA, CHLOR Etan, Inﬂ, Adal MTX 20–12.5 6–0
6 MTX, CSA Etan, Inﬂ None 15–None 2–0
7 MTX Etan, Inﬂ, Adal MTX, CSA None–None 2–1
8 MTX, CSA, CHLOR Etan, Inﬂ, Adal None 20–2.5 2–1
Legend: MTX: methotrexate; CSA: cyclosporine; CHLOR: chlorambucil; Etan: etanercept; Inﬂ:inﬂiximab; and Adal: adalimumab.
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with JIA associated uveitis patients [42], two of our patients failed to
respond to this immunosuppressive agent. Patients #5 and #8, before
or after switching of three anti-TNF drugs, have also tried a one-year
course of Chlorambucil treatment with long-term remission but ﬂare
up of the uveitis after cessation of the alkylating agent.
The mean systemic prednisolone dose needed before Rituximab
treatment was 18.75 mg/day (range 7.5–25 mg). At the end of follow-
up, only four out of six patients were still on daily systemic low-doses
of prednisolone (2.5–12.5 mg). The six patients treated with systemic
prednisolone, were able to greatly reduce the number of daily topical
corticosteroid drops, from amean of 3.25 (range 6–2) to a mean of 0.8
(range 2–0) times a day, and the remaining two patients were able to
discontinue topical therapy.
The mean follow-up time on Rituximab was 14.87±7.12 (SD)
months (range: 7–25). Four out of eight patients (#1, #2, #4 and #7)
underwent the 3rd Rituximab recall infusion after 8–12 months from
the ﬁrst one, and pt #3 underwent the 4th recall infusion after
21 months from the ﬁrst one, while the remaining received only the
ﬁrst full course of therapy of two infusions (Table 2).
Seven out of eight patients achieved the complete control of the
uveitis and were on persistent clinical remission at the last visit.
Patient #1 displayed a recurrence of anterior uveitis that resolved
with topical corticosteroids, at 10th month after the ﬁrst full course of
Rituximab, Patient # 3 had two recurrences respectively at 8th and
21 months, and underwent to an early recall 3rd and 4th infusion.
The decrease in uveitis activity was evident around the 4th–5th
month after the ﬁrst infusion. Snellen visual acuity measurements ofTable 2





































































Legend. NLP: no light perception.each patient at the beginning of Rituximab and at last visit are shown
in Table 2. None of the patients had a visual worsening during the
follow-up, while one patient (#2) had a visual acuity improvement of
the left eye being able to undergo cataract surgery while on clinical
remission on Rituximab treatment. No serious adverse events were
encountered in our treated patients.
The uveitis was on clinical remission in seven out of eight patients
at the last visit and improvement of intra-ocular inﬂammation was
noticeable around the 4th month after the ﬁrst infusion of Rituximab.
A corticosteroid sparing effect of Rituximab was noticeable in all
our patients; four out of six patients taking systemic prednisolone
were still on tapering daily low doses at the end of follow-up, but the
dosage was signiﬁcantly reduced compared to that required at the
beginning of Rituximab (mean reduction−11.7 mg/day; range−7.5
to −15), and two patients discontinued systemic steroid therapy at
the end of follow-up. There was also a discontinuation of concomitant
systemic immunosuppressants in ﬁve out of eight patients; only three
patients were taking methotrexate and/or cyclosporine in association
with Rituximab treatment at last visit.
Although experience in inﬂammatory eye disease is scarce, and
deﬁnite conclusions cannot be drawn by our series because of its
retrospective nature and the number of patients we believe that
Rituximab may be a promising treatment option for refractory uveitis
associated to JIA.
Take-home messages
• Rituximab, a humanized monoclonal antibody targeted to CD20, has
been used extensively for treating systemic lymphoma, rheumatoid
arthritis and other autoimmune diseases.
• Rituximab may be effective in the treatment of ocular inﬂammatory
diseases in particular the most aggressive, recalcitrant and sight-
threatening forms of inﬂammation such as uveitis in children
associated with JIA, as well as diseases not responsive to anti-TNF
alpha blocking agents.
• Inﬂammatory ocular diseases treated with Rituximab include:
scleritis, peripheral ulcerative keratitis, keratocnjunctivitis sicca,
uveitis, ocular cicatricial pemphigoid and intraocular lymphoma.
• Rituximab does not cure the disease and recurrences of inﬂamma-
tion are possible; retreatment may be required after variable
periods of clinical remission.
• Studies in larger numbers of patients are needed to better evaluate
the efﬁcacy, dosing regimen, and safety.
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